TAVIPILOT Soft
Guidance for Transcatheter Aortic Valve Implantation (TAVI)
Approved/CommercialFDA-cleared, first commercial use reported
Key Facts
Indication
Guidance for Transcatheter Aortic Valve Implantation (TAVI)
Phase
Approved/Commercial
Status
FDA-cleared, first commercial use reported
Company
About Carvolix
Carvolix is a publicly traded French MedTech company founded by Truffle Capital with the ambition to become a global leader in treating structural heart disease and ischemic stroke. The company leverages a unique business builder model, integrating three synergistic entities (Caranx Medical, Artedrone, and its legacy business) to develop AI- and imaging-driven mini-robots and next-generation heart valves. With its first product, TAVIPILOT Soft, already FDA-cleared and in commercial use, and a robotic system in clinical trials, Carvolix is positioned to address massive treatment gaps in TAVI, mitral regurgitation, and mechanical thrombectomy.
View full company profile